INBX financial statements
The full income statement, balance sheet, and cash-flow statement for Inhibrx Biosciences Inc. (INBX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| Revenue | 1.30M+550.0% | 200K-88.9% | 1.80M | |
| 136M-58.9% | 332M+50.1% | 221M | ||
| Research & development | 113M-44.5% | 204M+6.3% | 192M | |
| Selling, general & administrative | 23.3M-81.8% | 128M+335.3% | 29.4M | |
| General & administrative | 23.3M-81.8% | 128M+335.3% | 29.4M | |
| Operating income | -135M+59.3% | -331M-51.2% | -219M | |
| Interest expense | 12.2M-9.6% | 13.5M-57.6% | 31.8M | |
| Other non-operating income | -381K-608.0% | 75.0K+112.9% | -580K | |
| Equity-method income | — | 0.00+100.0% | -1.63M | |
| Pre-tax income | -140M-108.3% | 1.69B+804.0% | -240M | |
| Income tax | 2.00K+0.0% | 2.00K-33.3% | 3.00K | |
| Net income | -140M-108.3% | 1.69B+799.2% | -241M | |
| -$9.04-108.0% | $112.62+649.9% | -$20.48 | ||
| EPS (basic) | -$9.04-107.9% | $114.01+656.7% | -$20.48 | |
| Weighted-avg shares (basic) | 15.5M+4.6% | 14.8M+25.6% | 11.8M | |
| Weighted-avg shares (diluted) | 15.5M+3.4% | 15.0M+27.2% | 11.8M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| 133M-17.2% | 160M-45.7% | 295M | ||
| Cash & equivalents | 124M-18.6% | 153M-45.1% | 278M | |
| Prepaid expenses | 8.44M+14.3% | 7.38M-55.7% | 16.7M | |
| Other current assets | 238K-37.7% | 382K+4.4% | 366K | |
| 146M-19.0% | 181M-41.3% | 308M | ||
| Property, plant & equipment | 3.73M-39.8% | 6.20M-3.4% | 6.42M | |
| Operating lease right-of-use | 5.54M-24.6% | 7.34M+148.6% | 2.95M | |
| Other non-current assets | 4.38M-35.9% | 6.83M+115.9% | 3.16M | |
| 33.8M-17.0% | 40.7M-27.7% | 56.3M | ||
| Accounts payable | 5.94M-35.7% | 9.24M-15.6% | 11.0M | |
| Accrued liabilities | 25.5M-14.6% | 29.9M-31.0% | 43.3M | |
| Current lease liability | 2.33M+45.8% | 1.59M-22.7% | 2.06M | |
| 138M+193.5% | 47.2M-82.2% | 264M | ||
| Long-term debt | 101M | 0.00-100.0% | 207M | |
| Non-current lease liability | 4.13M-36.0% | 6.45M+481.4% | 1.11M | |
| Operating lease liability (total) | 6.45M-19.8% | 8.05M+153.6% | 3.17M | |
| 7.99M-94.0% | 134M+207.1% | 43.5M | ||
| Preferred stock | 0.00 | 0.00 | 0.00 | |
| Common stock | 1.00K+0.0% | 1.00K-80.0% | 5.00K | |
| Additional paid-in capital | 254M+6.0% | 240M-63.5% | 657M | |
| Retained earnings | -246M-132.0% | -106M+82.7% | -614M | |
| Total liabilities & equity | 146M-19.0% | 181M-41.3% | 308M | |
| Common shares issued | 14.6M+0.7% | 14.5M-69.4% | 47.4M | |
| Common shares outstanding | 14.6M+0.7% | 14.5M-69.4% | 47.4M | |
| Shares outstanding (cover) | 14.6M+0.9% | 14.5M | — | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| -130M+33.2% | -194M-0.6% | -193M | ||
| Depreciation & amortization | 2.48M+8.7% | 2.29M+91.9% | 1.19M | |
| Share-based compensation | 11.1M-81.0% | 58.5M+135.5% | 24.8M | |
| Change in receivables | -200K-208.1% | 185K-65.4% | 535K | |
| Change in payables | -3.30M-118.4% | 17.9M+748.9% | 2.11M | |
| -28.0K+98.9% | -2.60M+43.5% | -4.59M | ||
| Capital expenditure | 31.0K-98.8% | 2.60M-43.5% | 4.59M | |
| Free cash flow | -130M+34.1% | -197M+0.5% | -198M | |
| Acquisitions | 0.00 | 0.00 | 0.00 | |
| Proceeds from sale of PP&E | 3.00K | 0.00 | — | |
| 101M+41.5% | 71.7M-64.5% | 202M | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | 0.00 | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | |
| Net change in cash | -28.4M+77.4% | -125M-3187.7% | 4.06M | |
| Interest paid | 8.90M-22.6% | 11.5M-56.9% | 26.7M | |
| Income taxes paid | 2.00K+0.0% | 2.00K-33.3% | 3.00K | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | |
| Market cap | 1.15B+417.6% | 223M | — | |
| P/E | — | 0.1× | — | |
| P/S | 887.7×-20.4% | 1114.6× | — | |
| P/B | 144.4×+8551.0% | 1.7× | — | |
| Earnings yield | — | 757.0% | — | |
| Source filing | 10-K | 10-K | 10-K |
About this data
Source: INBX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all INBX filings on SEC EDGAR → Not investment advice.